



I. Corporate Profile

BurnsAdler is a specialty pharmaceutical company with unique worldwide product supply, marketing and distribution relationships. Our management team has vast experience in an array of international pharmaceutical and investment banking functions, and we bring this specific knowledge to bear for our development partners. The BurnsAdler value proposition is as follows:

- Experience in successfully launching 12 products in 17 countries since 2000.
- Focus on international commercialization in South America, Europe, the Caribbean and Canada.
- Partner with companies seeking to maximize sales in non-traditional and complex markets.
- Promote and distribute products which have not been introduced or may be under-performing.
- Achieve superior sales results via direct promotion or through partnering with the strongest promotion and distribution companies in each geographic and therapeutic area.
- Ability to immediately take advantage of BurnsAdler's relationships with over 200 pharmaceutical and medical device companies worldwide, as well as our proprietary systems and proven processes.

II. Strategy & Select Partners

BurnsAdler partners with other pharmaceutical companies to generate earnings from untapped or under performing international markets. We use our legal, regulatory and marketing resources to obtain marketing authorizations quickly and to maximize product sales. As well, we manage the local promotional efforts in each country using proprietary systems and proven processes. Select U.S., European and Canadian companies our team has worked with on international commercialization include:



POHL BOSKAMP



STRATEGIC INVESTMENTS™ LLC



III. Strategic Benefits

- While most specialty pharmaceutical companies focus on maximizing sales in the United States and Western Europe, BurnsAdler provides cost-effective promotion and distribution in other, non-traditional markets.
- BurnsAdler serves as both the customer and as the single point of contact for all marketing, sales, logistics and regulatory affairs in these selected markets.
- With 15 new registrations and 15 trademark filings in process in 2004, we have the market intelligence, experience and technical expertise necessary to achieve the highest yield from each product.
- One of our key missions is providing patient access to new medications in non-traditional markets.

(Continued on Reverse)

IV. Focus Areas

Our geographic areas of focus for out-licensing and international distribution include:

- Latin America
- Puerto Rico and the Caribbean
- Canada
- Europe
- Far East

Our therapeutic areas of focus include:

- Orphan status medications
- Cardiovascular
- CNS
- Hospital/ Critical Care
- Oncology
- Orthopaedic
- Gastrointestinal
- Anti-Infectives

V. Track Record

- Six products licensed since beginning of 2003.
- Currently launching products in the United States, Latin America, Canada and the Caribbean.
- Since 2000, our team has successfully launched products in 17 countries.
- Since 2000, our regulatory and legal affairs teams have filed or processed 50 product registrations dossiers and nearly 100 trademark applications.
- Founded and built King Pharmaceuticals' International Division. Annual revenues for the division exceeded \$75 million within three years from start-up.
- In 2004, we have 15 new registration and 15 trademark filings in process.

VI. Contact Information

We are very interested in evaluating partnership/ licensing and acquisition opportunities. If you have any products which you think may be of interest, please contact:

Bryan Somerville – Executive Vice President
6100 Fairview Road, Suite 725
Charlotte, North Carolina 28210
bsomerville@burnsadler.com
Phone: +1.704.552.8410 Ext. 223 • Fax: +1.704.552.8411